Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer Read more about Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer
Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates Read more about Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates
Bone Therapeutics announces 2019 full year results Read more about Bone Therapeutics announces 2019 full year results
Bone Therapeutics: Information on the total number of voting rights and shares (February 2020) Read more about Bone Therapeutics: Information on the total number of voting rights and shares (February 2020)
Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the ORS Read more about Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the ORS
Bone Therapeutics: Information on the total number of voting rights and shares (January 2020) Read more about Bone Therapeutics: Information on the total number of voting rights and shares (January 2020)
Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position Read more about Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position
Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference Read more about Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference
Bone Therapeutics: Information on the total number of voting rights and shares (December 2019) Read more about Bone Therapeutics: Information on the total number of voting rights and shares (December 2019)
Bone Therapeutics advances JTA-004 into pivotal Phase III study Read more about Bone Therapeutics advances JTA-004 into pivotal Phase III study
